In a report released on August 5, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $48.00. The company’s shares closed last Friday at $53.50.
According to TipRanks, Wang is a 5-star analyst with an average return of 14.7% and a 49.01% success rate. Wang covers the Healthcare sector, focusing on stocks such as Bluebird Bio, Alnylam Pharma, and BioCryst.
Currently, the analyst consensus on PTC Therapeutics is a Moderate Buy with an average price target of $52.00, representing a (2.80)% downside. In a report released on August 5, Credit Suisse also maintained a Hold rating on the stock with a $55.00 price target.
PTCT market cap is currently $3.82B and has a P/E ratio of (6.83).
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
Read More on PTCT:
- Barclays Sticks to Their Buy Rating for TJX Companies (TJX)
- Barclays Reaffirms Their Buy Rating on Palomar Holdings (PLMR)
- Block (SQ): New Buy Recommendation for This Technology Giant
- Fleetcor Technologies (FLT) Gets a Buy from Barclays
- Robert W. Baird Sticks to Their Buy Rating for Western Digital (WDC)